AnaptysBio - Anaptys Announces Stock Repurchase Plan
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Listen to Short Takes on Deep Science
Anaptys Publications and Relevant Literature
Pipeline
Overview
Rosnilimab
ANB033
ANB101
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
See Where We Work
Total Rewards Program Highlights
Get to Know Our Team
Join Team Anaptys!
Contact
Toggle
Home
Anaptys Announces Stock Repurchase Plan
Anaptys Announces Stock Repurchase Plan
Home
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Home
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Home
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
Home
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Home
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
Home
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Home
Anaptys Announces Participation in September Investor Conferences
Anaptys Announces Participation in September Investor Conferences
Home
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Home
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
Home
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Home
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Home
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
Home
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update